The potential adverse effects of hypodermic glucagon‐like peptide ‐1 receptor agonist on patients with type 2 diabetes: A population‐based study

The potential adverse effects of hypodermic glucagon‐like peptide ‐1 receptor agonist on patients with type 2 diabetes: A population‐based study

Abstract Background Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs), a class of injectable antidiabetic drugs, have shown significant efficacies in improving glycemic and weight control in patients with type 2 diabetes (T2D). However, the long‐term safety of GLP‐1 RAs remains insufficiently st...

Full description

Saved in:
Bibliographic Details
Main Authors: Zhiyuan Cheng, Shuang Wang, Fu‐rong Li, Cheng Jin, Chunbao Mo, Jing Zheng, Xia Li, Fengchao Liang, Jinkui Yang, Dongfeng Gu
Format: Article
Language:English
Published: Wiley 2024-10-01
Series:Journal of Diabetes
Subjects:
clinical adverse outcomes
GLP‐1 receptor agonists
type 2 diabetes
Online Access:https://doi.org/10.1111/1753-0407.70013
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items